(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 207.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 332.69%, and while it is forecast to beat the US market's average forecast revenue growth rate of 57.21%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $10,299,000.On average, 5 Wall Street analysts forecast TNXP's revenue for 2026 to be $1,028,233,435, with the lowest TNXP revenue forecast at $253,902,246, and the highest TNXP revenue forecast at $2,516,411,495. On average, 4 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,079,508,499, with the lowest TNXP revenue forecast at $556,700,693, and the highest TNXP revenue forecast at $1,626,104,919.
In 2028, TNXP is forecast to generate $1,330,042,653 in revenue, with the lowest revenue forecast at $1,277,872,572 and the highest revenue forecast at $1,369,140,773.